All feline diagnoses

Your cat was diagnosed with GI Lymphoma, Small Cell (Low Grade). Most common form of feline lymphoma. Alimentary lymphoma is the most common anatomical form in cats. UK incidence ~32/100,000 cats. Compare 3 treatment options for cats including Chlorambucil + Prednisolone, Cyclophosphamide Rescue (Relapsed Small Cell), Prednisolone Alone — with survival times, costs, and what to expect during treatment.

🐈

GI Lymphoma, Small Cell (Low Grade)

GI-localised

BreedsSiamese (historical, recent data equivocal)
feline

Round Cell

About This Cancer

Small cell (low-grade) gastrointestinal lymphoma is the most common cancer in cats and the most common form of feline lymphoma. It arises from lymphocytes — most often T-cells — that normally reside in the lining of the intestinal wall. These malignant lymphocytes accumulate gradually, disrupting the intestine's ability to absorb nutrients properly. Affected cats typically show chronic, slowly progressive signs such as weight loss, intermittent vomiting, decreased appetite, or diarrhoea. Because these symptoms closely mimic inflammatory bowel disease (IBD), and because distinguishing the two conditions can require full-thickness intestinal biopsies, diagnosis can be challenging. The good news is that small cell GI lymphoma generally responds well to oral chemotherapy (chlorambucil and prednisolone), with many cats achieving remission for one to three years or longer and maintaining an excellent quality of life throughout treatment.

WHO Modified Staging for Feline Lymphoma

Anatomical staging system adapted for cats. GI lymphoma is typically classified by histological grade (small cell vs large cell) rather than WHO stage, as most present as diffuse GI infiltration.

Stage ISingle tumour (extranodal) or single anatomic area (nodal)
Stage IITwo or more tumours on same side of diaphragm
Stage IIITumours on both sides of diaphragm
Stage IVLiver and/or spleen involvement
Stage VBone marrow or blood involvement
Prognostic Factors(4)
Histological gradeSmall cell carries dramatically better prognosis than large cell — MST >2 years vs ~3 months(Pope et al., 2015)
FeLV statusFeLV-positive cats have decreased remission times and poorer response to therapy
Achievement of complete responseCR significantly improves outcome — MST 318 days (CR) vs 85 days (PR) vs 27 days (NR) in high-grade(Collette et al., 2016)
Transformation risk9.9% of small-cell GI lymphoma cases transform to large cell. Median time to transformation ~615 days. Post-transformation MST ~24.5 days.(Wright et al., 2019)
Minimum Workup(8 steps)
1CRITICAL WARNING: Avoid administering prednisolone/prednisone BEFORE obtaining biopsy/cytology — corticosteroids can induce multi-drug resistance (MDR) and cause rapid tumour lysis, making subsequent histopathological diagnosis difficult or impossible. Complete diagnostic workup BEFORE starting any corticosteroid therapy.
2CBC, comprehensive chemistry panel
3FeLV/FIV testing
4Abdominal ultrasound (evaluate GI tract wall layering, mesenteric lymph nodes, liver, spleen)
5Thoracic radiographs
6Serum cobalamin (B12) level — frequently low in GI lymphoma
7Full-thickness intestinal biopsy with immunophenotyping (definitive — FNA often insufficient to distinguish from IBD)
8PCR for antigen receptor rearrangement (PARR) to confirm clonality if histopathology equivocal

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Chlorambucil + Prednisolone
~36 mo (24–43)
Cyclophosphamide Rescue (Relapsed Small Cell)
~35 mo
Prednisolone Alone
~3 mo (2–6)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.